Novavax
Stories
-
Novavax earns $125 million milestone as Sanofi launches Phase 3 flu-COVID combo trial in Europe
The payment was triggered when the fifth patient was dosed on Oct. 29, 2026. The study evaluates safety and immunogenicity of Nuvaxovid combined with Sanofi's Efluelda/Fluzone High-Dose vaccine in adults 60 and older.